
VolitionRx (VNRX) announces the expansion of its supply agreement with Fujifilm Vet Systems Co. in Japan, allowing the development and use of the Nu.Q Vet Feline Test. Published first on
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| VNRX | VolitionRX | 0.20 | -5.55 | -96.53% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.20 | -96.53% |

VolitionRx (VNRX) announces the expansion of its supply agreement with Fujifilm Vet Systems Co. in Japan, allowing the development and use of the Nu.Q Vet Feline Test. Published first on

VolitionRX Ltd. (($VNRX)) has held its Q3 earnings call. Read on for the main highlights of the call. VolitionRx delivered a strongly positive earnings call, highlighting progress in clinical validation,

Reports Q3 net loss $3.8M vs. a net loss of $5.4M in the prior-year period. CEO Cameron Reynolds said, “It has been a very full quarter as we have continued

VolitionRX ( ($VNRX) ) has shared an update. On November 10, 2026, Singapore Volition Pte. Limited, a wholly owned subsidiary of VolitionRx Limited, and Cameron Reynolds, the company’s chief executive

VolitionRX Ltd. (VNRX) is scheduled to report 3rd quarter earnings on 11/12/2026. Regarding Q3 estimates, Wall Street analysts expect VolitionRX Ltd. to post earnings of -$0.38 per share. Revenue expectations

VolitionRx (VNRX) has executed a non-binding Letter of Intent, or LOI, with Missionpharma A/S, a Danish global company in the filed of the sale and distribution of healthcare products and

VolitionRX ( ($VNRX) ) has provided an announcement. VolitionRx Limited reported that under a senior secured convertible promissory note originally issued to Lind Global Asset Management XII LLC pursuant to

The latest announcement is out from VolitionRX ( ($VNRX) ). In September 2026, VolitionRx Limited satisfied portions of its outstanding senior secured convertible notes held by Lind Global Asset Management

VolitionRx (VNRX) announced the presentation of an abstract at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference – ESMO MAP – in London this week. The

VolitionRX ( ($VNRX) ) has issued an update. On September 2, 2026, VolitionRx Limited and Lind Global Asset Management XII LLC entered into a waiver and consent that materially relaxes
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 30, 2027TBA | $8.30M | $-0.25 | $682.00K | 0.04 | -0.07 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.